8-K: Atossa Therapeutics Gets Nasdaq Bid Price Extension

Atossa Therapeutics, Inc. received a 180-day extension from Nasdaq to regain compliance with the minimum $1.00 bid price requirement, pushing the deadline to February 17, 2026.

Summary

• Atossa Therapeutics, Inc. (the "Company") received a notice from Nasdaq on February 21, 2025, indicating non-compliance with the minimum bid price requirement.
• The Company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days.
• The initial compliance period ended on August 20, 2025.
• On August 21, 2025, Nasdaq granted the Company a 180-day extension to regain compliance.
• The new deadline for compliance is February 17, 2026.
• The notice has no immediate effect on the listing or trading of the Company's common stock on Nasdaq.
• The Company intends to actively monitor its common stock's bid price and is committed to considering available options, including a potential reverse stock split, to regain compliance.

Sentiment

Score: 4

Explanation: The company is facing a significant listing compliance issue due to its low stock price. While an extension was granted, the underlying problem persists, and a potential reverse stock split, often viewed negatively, is being considered. This indicates ongoing challenges for the company's stock performance.

Positives

• Nasdaq granted a 180-day extension, providing more time to regain compliance.
• No immediate effect on the listing or trading of the Company's common stock.

Negatives

• The Company is not in compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• The common stock traded below $1.00 for 30 consecutive business days.
• Potential need for a reverse stock split, which can sometimes be viewed negatively by investors.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price requirement by February 17, 2026, could lead to delisting.
• Potential negative market perception or dilution if a reverse stock split is implemented.

Future Outlook

The Company plans to actively monitor its common stock's bid price and is committed to exploring all available options, including a potential reverse stock split, to regain compliance with Nasdaq's minimum bid price requirement by the extended deadline of February 17, 2026.

Management Comments

• The Company intends to actively monitor the bid price for its common stock, and is committed to considering available options to regain compliance with the minimum bid price requirement, including, if necessary, potentially effectuating a reverse stock split.

Industry Context

Nasdaq's minimum bid price rule is a standard listing requirement across all industries. Companies, particularly smaller or development-stage biotechnology firms, often face challenges maintaining this price, especially during periods of market volatility or when significant clinical milestones are pending. Receiving an extension is a common occurrence, providing a grace period to address the issue, often through operational improvements, positive news, or corporate actions like reverse stock splits.

Comparison to Industry Standards

• Nasdaq Listing Rule 5550(a)(2) requires a minimum closing bid price of $1.00 per share for continued listing, a standard benchmark for companies listed on the Nasdaq Capital Market.
• The 180-day compliance period and subsequent 180-day extension are standard procedures outlined by Nasdaq for companies failing to meet this requirement.
• Many companies, including peers in the biotechnology sector, have faced similar non-compliance issues and have utilized strategies such as reverse stock splits (e.g., Sorrento Therapeutics, Athersys, Inc. in the past) or positive clinical trial results to regain compliance.

Stakeholder Impact

• Shareholders: Face uncertainty regarding the stock's future listing status and potential dilution or negative perception from a reverse stock split. The current trading price below $1.00 also impacts liquidity and investor confidence.

Next Steps

• Actively monitor the bid price of common stock.
• Consider available options to regain compliance with the minimum bid price requirement.
• Potentially effectuate a reverse stock split if necessary.

Key Dates

Recommendation

While the company received an extension, the underlying issue of failing to meet the minimum bid price requirement remains. A potential reverse stock split, while a common solution, can be viewed negatively by the market. Investors should hold to see if the company can regain compliance through operational improvements or if the reverse split becomes necessary, and how the market reacts to such an event. The immediate delisting threat is mitigated by the extension, but the long-term stock performance is still uncertain.

Keywords

Atossa Therapeutics, ATOS, Nasdaq, minimum bid price, delisting, compliance, reverse stock split, stock market, biotechnology, pharmaceutical